ICUIMEDIUM SIGNALREGULATORY10-K

ICU Medical faces new FDA regulatory scrutiny with a 2025 warning letter regarding infusion pump modifications, while simultaneously progressing a strategic IV Solutions business divestiture.

The company has moved from resolving a 2021 FDA warning letter to addressing a new 2025 warning letter specifically targeting modifications to key infusion pump products, indicating ongoing regulatory compliance challenges in core product lines. The addition of tariff risks for Mexico and Costa Rica operations, combined with the advancing IV Solutions divestiture to Otsuka, suggests the company is navigating both operational restructuring and supply chain vulnerabilities.

Comparing 2026-02-19 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

The financial profile shows notable cash deployment with cash and equivalents declining substantially from $552.8M to $208.8M, while current assets decreased more moderately to $1.2B and current liabilities improved slightly to $498.9M. Operating cash flow softened to $179.8M alongside reduced share buyback activity of $8.8M. The overall picture suggests strategic capital allocation amid operational transitions, though the significant cash reduction warrants monitoring given the regulatory and operational headwinds.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
-62.2%
$552.8M→$208.8M

Cash declined 62.2% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Share Buybacks
Cash Flow
-26.9%
$12.0M→$8.8M

Buyback activity reduced 26.9% — capital being redeployed elsewhere or cash conservation underway.

Current Assets
Balance Sheet
-17.4%
$1.4B→$1.2B

Current assets declined 17.4% — monitor working capital adequacy and short-term liquidity.

Operating Cash Flow
Cash Flow
-11.9%
$204.0M→$179.8M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

Current Liabilities
Balance Sheet
-10.3%
$556.2M→$498.9M

Current liabilities reduced — improved short-term financial position and working capital health.

LANGUAGE CHANGES
NEW — 2026-02-19
PRIOR — 2025-02-27
ADDED
trade, tax or other policies that restrict imports or increase import tariffs for certain countries, particularly Mexico and Costa Rica; continuing pressures to reduce healthcare costs and inadequate coverage and reimbursement; our ability to comply with applicable laws, rules and regulations, including, without limitation, matters raised in a warning letter issued by the FDA in 2025, regarding modifications to our cleared MedFusion Model 4000 Syringe Infusion Pump and CADD Solis VIP Ambulatory Infusion Pump that could impact our continued commercial activity.
Principal risks and uncertainties include: We derive a significant portion of our revenues from non-U.S.
We are therefore subject to risks of doing business in other countries, including those related to tariffs, retaliatory counter measures and further escalation of trade tensions.
Continuing pressures to reduce healthcare costs and inadequate coverage and reimbursement may adversely affect our prices and volume.
ICU's product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needlefree IV connectors, peripheral IV catheters, sharps safety products, and sterile IV solutions offered on behalf of our joint venture; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products.
+7 more — sign up free →
REMOVED
trade, tax or other policies that restrict imports or increase import tariffs for certain countries, particularly Mexico, will escalate trade wars and will have a material adverse effect on our results of operations.
Continuing pressures to reduce healthcare costs and inadequate coverage and reimbursement may adversely affect our prices.
In particular, if we are unable to resolve or close-out the Warning Letter dated October 1, 2021, received by Smiths Medical ASD, Inc.
from the Minneapolis, Minnesota Facility following a February to March 2021 inspection, we could suffer significant sanctions which may impact our ability to sell products globally.
ICU's product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needlefree IV connectors, peripheral IV catheters, sharps safety products, and sterile IV solutions; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products.
+7 more — sign up free →
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →